China will issue special treasury bonds for healthcare.New policy boosts hope for innovative drugs.Horizontal competition in Taiji and Shanghai Shyndec Pharma may lead to spin-off/integration by 2025
What is covered in the Full Insight:
Medical Equipment Renewal Policy
Supporting Policies for Innovative Drug Industry
Investor Sentiment Towards China's Drug Industry
Competing Interests in the Chinese Pharmaceutical Landscape
Risk Factors
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.